The majority of studies on serum IL-18 levels in cancer patients do not provide concomitant information about the concentration of its antagonist, that is, IL-18BP or IL-18-inducible cytokines such as IFN-γ in the same blood samples. The gene discussed is IFNG; the disease is cancer.